Introduction

BOAS (Brachycephalic Obstructive Airway Syndrome) is a consequence of selective breeding for a shortened skull and “flat‑faced” appearance, where airway function can be compromised by the way the head and upper airway are shaped.

This matters because BOAS isn’t just a bit of noise. In some dogs it can progress to genuine breathing obstruction and episodes of respiratory distress, especially with heat, excitement, exercise, or stress.

BOAS in plain English: what it is and why it matters

BOAS is a group of structural problems that obstruct airflow in brachycephalic breeds. The American College of Veterinary Surgeons defines brachycephalic syndrome as the combination of stenotic nares (narrow nostrils), an elongated soft palate, and everted laryngeal saccules (tissue that can be pulled into the airway over time) (American College of Veterinary Surgeons, n.d.).

A simple way to picture BOAS is trying to breathe through a straw while someone gently pinches it. You can still move air, but it takes more effort, it’s noisier, and it gets worse with triggers like heat, exercise, excitement, and stress.

BOAS is not just snoring. Depending on the dog and severity, it can involve:

• Noisy breathing (especially with activity or excitement)
• Increased effort to breathe (working harder just to move air)
• Respiratory distress (struggling to breathe, sometimes suddenly)
• Poor exercise tolerance and slow recovery after activity
• Heat intolerance (overheating more easily and more dangerously)
• Sleep disturbance (restless sleep, waking, sometimes apnoea-like episodes)
• Regurgitation/reflux in some dogs
• In severe cases: collapse and life-threatening overheating events

One of the biggest problems is that BOAS signs are often normalised as “just how the breed breathes”. The reality is that many dogs are quietly coping until they hit a trigger (heat, stress, a big walk, a long car trip, a grooming visit, a respiratory infection).

The new research: what is Snoretox‑1?

A 2026 paper in The Veterinary Journal describes early research into an investigational injection called Snoretox‑1, trialled in six British bulldogs with moderate to severe BOAS (Sasse et al., 2026).

In broad terms, Snoretox‑1 is designed to increase local muscle tone in tissues that help support the upper airway. The therapy combines an active tetanus-toxin–derived neuromuscular stimulant with an inactivated “decoy” component, with the goal of allowing the active ingredient to work locally even when anti‑tetanus antibodies are present.

What the paper reported (results)

This was a small pilot study (six dogs), so it’s important to treat it as early evidence rather than a final answer. That said, the results reported in the paper were notable:

• All six dogs improved by at least one BOAS grade on a standardised respiratory grading scale (RFG) (Sasse et al., 2026).
• When the authors compared scores after placebo baseline with scores at time points up to 12 weeks after treatment, they reported a statistically significant improvement (p < 0.001) (Sasse et al., 2026).
• The paper reports that improvements lasted around 20 to 53 weeks after treatment (duration varied between dogs) (Sasse et al., 2026).
• Owner-reported changes were mixed: some owners rated breathing and activity as improved, while others reported little change over time (Sasse et al., 2026).

Side effects and adverse events reported in the paper

The paper reports:

• Two dogs developed excess salivation and difficulty eating (dysphagia) that lasted up to 5½ weeks, then resolved (Sasse et al., 2026).
• One dog died during the follow-up period from a genetic cardiac condition (ARVC) based on necropsy findings; the authors considered this unrelated to treatment (Sasse et al., 2026).

What this does not mean (yet)

Because this is early-stage research in a very small number of dogs, it does not yet tell us:

• how well this would work across a broader population of brachycephalic breeds (including pugs and French bulldogs)
• how it compares to established BOAS management options
• which dogs are most likely to benefit, and who won’t
• the full side-effect profile in larger numbers of patients
• the best dosing and re-dosing approach long-term

What owners should do right now

Even if new therapies arrive in the future, BOAS is still something worth taking seriously today.

If your brachycephalic dog has noisy breathing, struggles on walks, overheats easily, seems distressed when breathing, or takes a long time to recover after activity, it’s worth having a proper BOAS assessment and a practical plan. For many dogs, the biggest immediate wins are sensible heat management, realistic exercise choices, and addressing contributing factors like body condition and stress/excitement triggers.

Read the study

Sasse, A. et al. (2026) ‘Clinical observations of tetanus toxin plus decoy, Snoretox‑1, a novel targeted neuromuscular stimulant, in a pilot study of 6 British bulldogs with BOAS’, The Veterinary Journal, 317, 106636. Available at: https://doi.org/10.1016/j.tvjl.2026.106636 (Accessed: 24 April 2026).

Tags (comma-separated)

brachycephalic breeds, flat‑faced dogs, BOAS, breathing problems in dogs, veterinary research, dog welfare, respiratory distress in dogs, British bulldog health

Image SEO metadata (1 hero image suggestion)

• SEO file title: boas-brachycephalic-breeds-breathing-research-2026.jpg
• Alt text: Brachycephalic dog resting at home while an owner watches breathing calmly
• Caption: BOAS can involve noisy breathing, heat intolerance, and respiratory distress — not just snoring.
• Description: Documentary-style image of a brachycephalic dog in a normal home environment for an educational article explaining BOAS and summarising early research into an investigational injection (Snoretox‑1).

---

References

American College of Veterinary Surgeons (n.d.) Brachycephalic Syndrome. Available at: https://www.acvs.org/small-animal/brachycephalic-syndrome/ (Accessed: 24 April 2026).

Sasse, A., Norbury, L.J., McLean, T., Newport, M., House, A., Swift, D.W., Aliano, D., Smooker, P.M. and Conduit, R. (2026) ‘Clinical observations of tetanus toxin plus decoy, Snoretox‑1, a novel targeted neuromuscular stimulant, in a pilot study of 6 British bulldogs with BOAS’, The Veterinary Journal, 317, 106636. Available at: https://doi.org/10.1016/j.tvjl.2026.106636 (Accessed: 24 April 2026).

Sources:

• Web: https://www.acvs.org/small-animal/brachycephalic-syndrome/
• User-provided excerpt from: Sasse, A. et al. (2026) The Veterinary Journal, 317, 106636. https://doi.org/10.1016/j.tvjl.2026.106636